IDH2 mutant
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene IDH2
Variant mutant
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions IDH2 mutant indicates an unspecified mutation in the IDH2 gene.
Associated Drug Resistance
Category Variants Paths

IDH2 mutant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed USA 0
NCT03158389 Phase Ib/II Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 NCT Neuro Master Match - N²M² (NOA-20) (N²M²) Completed DEU 0
NCT03881735 Phase II Enasidenib Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation Withdrawn USA 0
NCT04945148 Phase II Metformin + Temozolomide Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) Recruiting ITA | FRA 0
NCT05756777 Phase I Gilteritinib + Ivosidenib Enasidenib + Gilteritinib A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT07089641 Phase I ERAS-801 ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (ERAS801-SARG) Recruiting USA 0
NCT04281498 Phase II Enasidenib + Ruxolitinib Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Completed USA | CAN 0
NCT03683433 Phase II Azacitidine + Enasidenib Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting USA 0
NCT06991101 Phase II Ruxolitinib + Temozolomide Temozolomide Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Not yet recruiting USA 0
NCT05183204 Phase II GDC-0084 + Metformin Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma Recruiting USA 0
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Withdrawn USA 0
NCT02428855 Phase II Dasatinib Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed USA 0
NCT02577406 Phase III Azacitidine Cytarabine Enasidenib An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) Completed USA | TUR | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 4
NCT06258018 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) Not yet recruiting ITA 0
NCT05441514 Phase I Cobimetinib + Enasidenib Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04729959 Phase II Atezolizumab + Tocilizumab Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma Active, not recruiting USA 0
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL 4
NCT05188508 Phase II Olaparib + Pembrolizumab + Temozolomide Pembrolizumab, Olaparib, and Temozolomide for People with Glioma Recruiting USA 0
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT03557359 Phase II Nivolumab Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Completed USA 0
NCT07177079 Phase I Decitabine + Venetoclax Azacitidine + Venetoclax Azacitidine + Venetoclax + Vitamin C Decitabine + Venetoclax + Vitamin C High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) Not yet recruiting USA 0
NCT02981940 Phase II Abemaciclib A Study of Abemaciclib in Recurrent Glioblastoma Active, not recruiting USA 0
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Completed USA 1
NCT06831526 Phase I Azeliragon + Temozolomide Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma Recruiting USA 0
NCT04015700 Phase I GNOS-PV01 + Rocakinogene sifuplasmid Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma Active, not recruiting USA 0
NCT06719362 Phase I M3T01 M3T01 + Temozolomide M3T01 + Pembrolizumab Fluorouracil + Leucovorin + M3T01 + Oxaliplatin + Pembrolizumab A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies Recruiting USA 0
NCT02492737 Phase I Vorasidenib Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation Completed USA | FRA 0
NCT05052957 Phase II Carmustine + Filgrastim + O6-benzylguanine + Temozolomide hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) Recruiting USA 0
NCT06095375 Phase I Regorafenib + Temozolomide Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) Active, not recruiting ITA 0
NCT05282459 Phase Ib/II Enasidenib Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Completed USA 0
NCT05222802 Phase I ERAS-801 A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) Active, not recruiting USA 0
NCT04774393 Phase Ib/II Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05345002 Phase II Retifanlimab + Tretinoin All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Recruiting USA 0
NCT02525692 Phase II Dordaviprone Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma Terminated USA 0
NCT05432804 Phase Ib/II Selinexor + Temozolomide Temozolomide Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment Suspended USA 0
NCT07243470 Phase Ib/II Tarlatamab + Temozolomide Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors (TARLATEM) Recruiting FRA 0
NCT05474378 Phase I Retroviral vector transduced B7-H3 CAR T cells B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme Recruiting USA 0
NCT05417594 Phase Ib/II AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03744390 Phase II Enasidenib IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome Active, not recruiting FRA 0
NCT04764474 Phase I HMPL-306 A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Terminated USA | ESP 0
NCT03825796 Phase II CPX-351 + Enasidenib Cytarabine + Enasidenib Enasidenib CPX-351 Plus Enasidenib for Relapsed AML Active, not recruiting USA 0
NCT03701295 Phase Ib/II Azacitidine + Pinometostat Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Completed USA 0
NCT04118036 Phase II Abemaciclib + Pembrolizumab Abemaciclib + Pembrolizumab In Glioblastoma Withdrawn USA 0
NCT04559230 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan in Recurrent Glioblastoma Recruiting USA 0
NCT05465954 Phase II NT-I7 + Pembrolizumab Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Recruiting USA 0
NCT06478212 Phase Ib/II Temozolomide + Vorasidenib Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma Recruiting USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT 2
NCT06413706 Phase II Abemaciclib + Temozolomide Temozolomide A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Recruiting USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS 1
NCT02858895 Phase II MDNA55 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed USA 0
NCT07110246 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas (PNOC037) Recruiting USA 0
NCT03139916 Phase II Bavituximab + Temozolomide Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Completed USA 0
NCT05326464 Phase III Tofacitinib Tofacitinib in Recurrent GBM Patients Active, not recruiting USA 0
NCT03970447 Phase II VAL-083 ADI-PEG 20 AZD1390 VT1021 Lomustine Regorafenib Temozolomide GDC-0084 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) Recruiting USA | FRA | DEU | CHE | CAN | AUS 0
NCT05432375 Phase I Tinostamustine Study of Tinostamustine for Adjuvant Treatment of Glioblastoma Active, not recruiting ESP | CHE 0
NCT06776250 Phase II Tarlatamab Study of How Safe and Effective Tarlatamab is in Brain Cancers Recruiting CAN 0
NCT07223034 Phase I lutetium Lu 177 vipivotide tetraxetan + Temozolomide A Study of 177Lu-PSMA-617 in People With Gliomas Recruiting USA 0
NCT03728335 Phase I Enasidenib Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Recruiting USA 0
NCT06297512 Phase II Doxorubicin + Temozolomide Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). Recruiting ITA 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT04203316 Phase II Enasidenib Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Active, not recruiting USA | CAN 0
NCT06934889 Phase I ABBV-637 + ERAS-801 ABBV-637 + Temozolomide ERAS-801 + Mirzotamab clezutoclax Mirzotamab clezutoclax + Temozolomide Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma Recruiting USA 0
NCT05627323 Phase I CHM-1101 CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma Active, not recruiting USA 0
NCT05588141 Phase Ib/II Zotiraciclib A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations Recruiting USA 0
NCT04396860 Phase II Temozolomide Ipilimumab + Nivolumab Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Active, not recruiting USA 0
NCT03991832 Phase II Durvalumab + Olaparib Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) Recruiting CAN 0
NCT04606316 Phase I Nivolumab Ipilimumab + Nivolumab Surgical Nivolumab And Ipilimumab For Recurrent GBM Active, not recruiting USA 0
NCT05406700 Phase I Niraparib Niraparib In Recurrent IDH 1/2 Gliomas Active, not recruiting USA 0
NCT04555577 Phase I Peposertib Temozolomide Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma Recruiting USA 0
NCT03878095 Phase II Ceralasertib + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Active, not recruiting USA 0
NCT01915498 Phase Ib/II Enasidenib Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation Completed USA | FRA 0
NCT05283109 Phase I P30-EPS + Poly ICLC ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) Active, not recruiting USA 0
NCT02632708 Phase I Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation Active, not recruiting USA | NLD | DEU 0
NCT05401097 Phase II Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax IDH Targeted/non- Targeted Vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Recruiting USA 0
NCT06636162 Phase I DSP-0390 Window of Opportunity Study of DSP-0390 in Gliomas Recruiting USA 0
NCT05376800 Phase I BI 907828 A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma Completed USA | ESP | BEL 0
NCT06161974 Phase II Olutasidenib + Temozolomide Study of Olutasidenib and Temozolomide in HGG Recruiting USA | NLD | GBR | DEU | CAN | AUS 0
NCT04762602 Phase I HMPL-306 A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Terminated USA | ESP 0
NCT02481154 Phase I Vorasidenib Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Completed USA 0
NCT05879120 Phase II Pembrolizumab Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma Withdrawn USA 0
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy Active, not recruiting USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT03749187 Phase I Pamiparib + Temozolomide BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) Recruiting USA 0
NCT02968940 Phase II Avelumab Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Completed USA 0
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma Terminated USA 0
NCT04629209 Phase II Dordaviprone A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma Withdrawn USA 0
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed USA | FRA 0
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA 0
NCT03922555 Phase I Decitabine and Cedazuridine ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas Recruiting USA 0
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib OLAParib COmbinations (OLAPCO) Terminated USA 0
NCT03718767 Phase II Nivolumab Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Active, not recruiting USA 0
NCT05743595 Phase I Personalized cancer vaccine + Retifanlimab Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting USA 0
NCT05463848 Phase II Olaparib + Pembrolizumab + Temozolomide Pembrolizumab Surgical Pembro +/- Olaparib W TMZ for RGBM Recruiting USA 0
NCT06809322 Phase III Vorasidenib Vorasidenib Maintenance for IDH Mutant Astrocytoma (VIGOR) Not yet recruiting NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT 0
NCT07075016 Phase III Azacitidine + Ivosidenib + Venetoclax Azacitidine + Ivosidenib Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) Recruiting SWE | NOR | NLD | LTU | ITA | IRL | GBR | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT 0